Sangamo
As a rival to CRISPR in the gene-editing field, zinc finger nuclease technology is making a name for itself. LSIPR hears from Sandy Macrae, CEO of Sangamo Therapeutics, one of the key players in this area.
While CRISPR gene-editing and the battle over its patents continue to dominate headlines, a lesser known contender is making a name for itself, partly thanks to the drive of one company.
“Without a doubt, zinc finger nuclease (ZFN) editing is superior to CRISPR editing,” claims Sandy Macrae, president and CEO of Sangamo Therapeutics based in Richmond, California.
Sangamo’s proprietary technology is based on a naturally-occurring class of proteins called zinc finger DNA-binding proteins (ZFPs), which recognise and bind to specific sequences of DNA. A nuclease, which is a functional domain that cuts DNA, is attached to the ZFP portion to make a ZFN.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sangamo Therapeutics, Sandy Macrae, ZFN, zinc finger nuclease technology, CRISPR, gene-editing, genetics, Kite, Gilead
